Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Incyte (INCY) PT Raised to $175 at BMO Capital; 'We Like Risk/Reward Heading into ECHO-301'
February 15, 2018 3:06 PM ESTBMO Capital raised its price target on Incyte (NASDAQ: INCY) to $175.00 (from $172.00) while maintaining an Outperform rating.
Analyst M. Ian Somaiya commented, "Despite strong fundamentals and a rich pipeline, investor focus remains singularly on the upcoming epacadostat Phase 3 melanoma data (ECHO-301), with positive... More
UPDATE: SunTrust Robinson Humphrey Reiterates Bullish View on Incyte (INCY)
February 15, 2018 2:35 PM EST(Updated - February 15, 2018 2:50 PM EST)
(updated to expand analyst comment)
SunTrust Robinson Humphrey analyst Peter Lawson reiterated a Buy rating and $155 price target on Incyte (NASDAQ: INCY)
Lawson calls Q4 "Minor Jakafi Miss, but Focus on Epacadostat Readouts in 2018." The... More
Incyte (INCY) Q4 Revenues Beat
February 15, 2018 7:05 AM ESTIncyte (NASDAQ: INCY) reported Q4 EPS of ($0.71), which may not compare to the analyst estimate of ($0.40). Revenue for the quarter came in at $444 million versus the consensus estimate of $414.16 million.
Issues Jakafi FY 2018 guidance $1.35-1.40 billion
For earnings history and earnings-related data on Incyte (INCY) click here.
... More